Cormorant Asset Management
Boston, Massachusetts, United StatesFounded 2013
Cormorant Asset Management focuses on healthcare and life sciences, particularly biotechnology. They invest across both public and private markets, seeking innovative companies developing transformative therapies.
Portfolio
18
Fund Size
$3.5B
Top Stage
Series A
Last 12 Mo
3
Team
RK
Raymond Kelleher
Managing Director
Stage Distribution
Portfolio
18 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Aspen Neuroscience | Series C | $115M | Nov 2025 |
| Attovia Therapeutics | Series C | $90M | Apr 2025 |
| Garuda Therapeutics | Series A | $50M | Mar 2025 |
| Numab Therapeutics AG | Series C | $55M | Jan 2025 |
| Axonis Therapeutics | Series A | $115M | Oct 2024 |
| Triveni Bio Inc. | Series B | $115M | Oct 2024 |
| Averto Medical Inc | Series A | $30.5M | May 2024 |
| Supira Medical, Inc. | Series D | $40M | Nov 2023 |
| Rapport Therapeutics | Series B | $150M | Aug 2023 |
| Arkuda Therapeutics | Series B | $64M | Feb 2022 |
| Freenome | Series D | $300M | Dec 2021 |
| Shoreline Biosciences | Growth | $140M | Nov 2021 |
| Interius BioTherapeutics | Series A | $76M | May 2021 |
| Shoreline Biosciences | Series A | $43M | Apr 2021 |
| Prometheus Biosciences | Growth | $130M | Nov 2020 |
| BioShin Limited | Series A | $60M | Sep 2020 |
| Akero Therapeutics | Series B | $70M | Dec 2018 |
| Innovent Biologics, Inc. | Series E | $150M | Apr 2018 |
Top Co-Investors
Perceptive Advisors4 shared
Janus Henderson Investors4 shared
OrbiMed3 shared
Logos Capital3 shared
Atlas Venture3 shared
Deep Track Capital2 shared
Goldman Sachs Alternatives2 shared
ARCH Venture Partners2 shared
RA Capital Management2 shared
Bain Capital Life Sciences2 shared
T. Rowe Price Associates, Inc.2 shared
Eventide Asset Management2 shared
Rock Springs Capital2 shared
venBio2 shared
Pfizer Ventures2 shared
Ally Bridge Group2 shared
Surveyor Capital2 shared
Sofinnova Partners2 shared
Sanofi Ventures1 shared
Last updated: 1 March 2026